Successful examples of clinically approved inhibitors of CAMs are limited to three monoclonal antibodies (mAbs): natalizumab and vedolizumab, which target leukocyte expressed α4β7 integrins and are approved for the treatment of IBD (43) and crizanlizumab (anti-P-selectin mAb)-approved in 2019 for vaso-occlusive crisis (VOC) in SCD (29). Here, SELP is linked to Schnyder corneal dystrophy.